Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Scribe Therapeutics, Inc.SCTX · Entity 5494 | Director · See Remarks | July 24, 2026 | July 29, 2026 |
| Whitehawk Therapeutics, Inc.WHWK · Entity 6074 | Director · 10% owner · See remarks | June 12, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Scribe Therapeutics, Inc.
Report date July 24, 2026 · Filed July 29, 2026
Jointly reported with Aghazadeh Behzad, Avoro Capital Advisors LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectSee footnotes | 3,030,983 |
Reported balance
After 2026-07-24 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-07-24 · Purchase · Acquired 2,333,333 · Balance 3,030,983 F1: The shares reported on this line were purchased from underwriters in the Issuer's initial public offering (the "IPO") at the initial public offering price of $15.00 per share. Of such shares, 2,066,666 shares were purchased on behalf of Avoro Life Sciences Fund LLC ("Avoro Life Sciences") and 266,667 shares were purchased on behalf of Avoro Ventures Fund L.P. ("Avoro Ventures Fund" and, together with Avoro Life Sciences, the "Funds"). F6: The amount reported in Column 5 includes 697,650 shares of Common Stock issuable upon conversion of shares of the Issuer's Series B Preferred Stock held by the Funds, which shares were reported on an as-converted basis in the Reporting Persons' Form 3 filed on July 23, 2026. Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-0.1689 basis at the option of the holder and converted automatically into Common Stock, without the payment of any consideration, upon the closing of the IPO on July 27, 2026. No transaction is reported in Table I or Table II with respect to the conversion. F4: The securities reported herein are held directly by Avoro Life Sciences and Avoro Ventures Fund. Avoro Capital Advisors LLC ("Avoro Capital Advisors") serves as investment adviser to Avoro Life Sciences, and Avoro Ventures LLC ("Avoro Ventures") serves as investment adviser to Avoro Ventures Fund. Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures. By virtue of these relationships, each of the Reporting Persons may be deemed to beneficially own the securities held by the Funds. F5: Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The shares reported herein are held on behalf of the Funds and other managed accounts, within the meaning of Rule 16a-1(a)(2). |
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectSee footnotes | 3,080,983 |
Reported balance
After 2026-07-24 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2026-07-24 · Purchase · Acquired 50,000 · Balance 3,080,983 F2: The shares reported on these lines were purchased on behalf of Avoro Life Sciences in open market transactions on the dates provided in Column 2. F6: The amount reported in Column 5 includes 697,650 shares of Common Stock issuable upon conversion of shares of the Issuer's Series B Preferred Stock held by the Funds, which shares were reported on an as-converted basis in the Reporting Persons' Form 3 filed on July 23, 2026. Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-0.1689 basis at the option of the holder and converted automatically into Common Stock, without the payment of any consideration, upon the closing of the IPO on July 27, 2026. No transaction is reported in Table I or Table II with respect to the conversion. F4: The securities reported herein are held directly by Avoro Life Sciences and Avoro Ventures Fund. Avoro Capital Advisors LLC ("Avoro Capital Advisors") serves as investment adviser to Avoro Life Sciences, and Avoro Ventures LLC ("Avoro Ventures") serves as investment adviser to Avoro Ventures Fund. Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures. By virtue of these relationships, each of the Reporting Persons may be deemed to beneficially own the securities held by the Funds. F5: Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The shares reported herein are held on behalf of the Funds and other managed accounts, within the meaning of Rule 16a-1(a)(2). |
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectSee footnotes | 3,088,888 |
Reported balance
After 2026-07-28 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2026-07-28 · Purchase · Acquired 7,905 · Balance 3,088,888 F2: The shares reported on these lines were purchased on behalf of Avoro Life Sciences in open market transactions on the dates provided in Column 2. F3: Of the 3,088,888 shares reported in Column 5, 2,598,973 shares are held by Avoro Life Sciences and 489,915 shares are held by Avoro Ventures Fund. F6: The amount reported in Column 5 includes 697,650 shares of Common Stock issuable upon conversion of shares of the Issuer's Series B Preferred Stock held by the Funds, which shares were reported on an as-converted basis in the Reporting Persons' Form 3 filed on July 23, 2026. Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-0.1689 basis at the option of the holder and converted automatically into Common Stock, without the payment of any consideration, upon the closing of the IPO on July 27, 2026. No transaction is reported in Table I or Table II with respect to the conversion. F4: The securities reported herein are held directly by Avoro Life Sciences and Avoro Ventures Fund. Avoro Capital Advisors LLC ("Avoro Capital Advisors") serves as investment adviser to Avoro Life Sciences, and Avoro Ventures LLC ("Avoro Ventures") serves as investment adviser to Avoro Ventures Fund. Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures. By virtue of these relationships, each of the Reporting Persons may be deemed to beneficially own the securities held by the Funds. F5: Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The shares reported herein are held on behalf of the Funds and other managed accounts, within the meaning of Rule 16a-1(a)(2). |
Filing footnotes · ownership attribution and instrument terms
F1: The shares reported on this line were purchased from underwriters in the Issuer's initial public offering (the "IPO") at the initial public offering price of $15.00 per share. Of such shares, 2,066,666 shares were purchased on behalf of Avoro Life Sciences Fund LLC ("Avoro Life Sciences") and 266,667 shares were purchased on behalf of Avoro Ventures Fund L.P. ("Avoro Ventures Fund" and, together with Avoro Life Sciences, the "Funds").
F2: The shares reported on these lines were purchased on behalf of Avoro Life Sciences in open market transactions on the dates provided in Column 2.
F3: Of the 3,088,888 shares reported in Column 5, 2,598,973 shares are held by Avoro Life Sciences and 489,915 shares are held by Avoro Ventures Fund.
F4: The securities reported herein are held directly by Avoro Life Sciences and Avoro Ventures Fund. Avoro Capital Advisors LLC ("Avoro Capital Advisors") serves as investment adviser to Avoro Life Sciences, and Avoro Ventures LLC ("Avoro Ventures") serves as investment adviser to Avoro Ventures Fund. Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures. By virtue of these relationships, each of the Reporting Persons may be deemed to beneficially own the securities held by the Funds.
F5: Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The shares reported herein are held on behalf of the Funds and other managed accounts, within the meaning of Rule 16a-1(a)(2).
F6: The amount reported in Column 5 includes 697,650 shares of Common Stock issuable upon conversion of shares of the Issuer's Series B Preferred Stock held by the Funds, which shares were reported on an as-converted basis in the Reporting Persons' Form 3 filed on July 23, 2026. Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-0.1689 basis at the option of the holder and converted automatically into Common Stock, without the payment of any consideration, upon the closing of the IPO on July 27, 2026. No transaction is reported in Table I or Table II with respect to the conversion.
Whitehawk Therapeutics, Inc.
Report date June 12, 2026 · Filed June 15, 2026
Jointly reported with Aghazadeh Behzad, Avoro Capital Advisors LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.16 · Expires 2036-06-12 | Direct | 38,040 |
Reported balance
After 2026-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-12 · Grant · Acquired 38,040 · Balance 38,040 F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026. F2: This Form 4 is filed by Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro Capital Advisors"), Avoro Ventures LLC, a Delaware limited liability company ("Avoro Ventures") and Behzad Aghazadeh ("Dr. Aghazadeh", and together with Avoro Capital Advisors and Avoro Ventures, the "Reporting Persons"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures LLC. F3: The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026.
F2: This Form 4 is filed by Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro Capital Advisors"), Avoro Ventures LLC, a Delaware limited liability company ("Avoro Ventures") and Behzad Aghazadeh ("Dr. Aghazadeh", and together with Avoro Capital Advisors and Avoro Ventures, the "Reporting Persons"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures LLC.
F3: The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 28, 2026 Filed Jul 29, 2026 01:30 UTC | Scribe Therapeutics, Inc. SCTX · Entity 5494 | PurchaseCommon Stock, par value $0.0001 per share | 7,905 | $18.25 | $144,266.25 |
DisclosureSEC source: 0000902664-26-003270 · ownership.xml · nonDerivative · entry 3 Aghazadeh Behzad · CIK 0001701815 · Director · 10% owner · See Remarks Avoro Capital Advisors LLC · CIK 0001633313 · Director · 10% owner · See Remarks Avoro Ventures LLC · CIK 0001879253 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 3,088,888 F2 · price: The shares reported on these lines were purchased on behalf of Avoro Life Sciences in open market transactions on the dates provided in Column 2. F3 · balance_after: Of the 3,088,888 shares reported in Column 5, 2,598,973 shares are held by Avoro Life Sciences and 489,915 shares are held by Avoro Ventures Fund. F6 · balance_after: The amount reported in Column 5 includes 697,650 shares of Common Stock issuable upon conversion of shares of the Issuer's Series B Preferred Stock held by the Funds, which shares were reported on an as-converted basis in the Reporting Persons' Form 3 filed on July 23, 2026. Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-0.1689 basis at the option of the holder and converted automatically into Common Stock, without the payment of any consideration, upon the closing of the IPO on July 27, 2026. No transaction is reported in Table I or Table II with respect to the conversion. F4 · ownership.nature: The securities reported herein are held directly by Avoro Life Sciences and Avoro Ventures Fund. Avoro Capital Advisors LLC ("Avoro Capital Advisors") serves as investment adviser to Avoro Life Sciences, and Avoro Ventures LLC ("Avoro Ventures") serves as investment adviser to Avoro Ventures Fund. Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures. By virtue of these relationships, each of the Reporting Persons may be deemed to beneficially own the securities held by the Funds. F5 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The shares reported herein are held on behalf of the Funds and other managed accounts, within the meaning of Rule 16a-1(a)(2). Read SEC document |
| July 24, 2026 Filed Jul 29, 2026 01:30 UTC | Scribe Therapeutics, Inc. SCTX · Entity 5494 | PurchaseCommon Stock, par value $0.0001 per share | 50,000 | $22.31 | $1,115,500.00 |
DisclosureSEC source: 0000902664-26-003270 · ownership.xml · nonDerivative · entry 2 Aghazadeh Behzad · CIK 0001701815 · Director · 10% owner · See Remarks Avoro Capital Advisors LLC · CIK 0001633313 · Director · 10% owner · See Remarks Avoro Ventures LLC · CIK 0001879253 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 3,080,983 F2 · price: The shares reported on these lines were purchased on behalf of Avoro Life Sciences in open market transactions on the dates provided in Column 2. F6 · balance_after: The amount reported in Column 5 includes 697,650 shares of Common Stock issuable upon conversion of shares of the Issuer's Series B Preferred Stock held by the Funds, which shares were reported on an as-converted basis in the Reporting Persons' Form 3 filed on July 23, 2026. Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-0.1689 basis at the option of the holder and converted automatically into Common Stock, without the payment of any consideration, upon the closing of the IPO on July 27, 2026. No transaction is reported in Table I or Table II with respect to the conversion. F4 · ownership.nature: The securities reported herein are held directly by Avoro Life Sciences and Avoro Ventures Fund. Avoro Capital Advisors LLC ("Avoro Capital Advisors") serves as investment adviser to Avoro Life Sciences, and Avoro Ventures LLC ("Avoro Ventures") serves as investment adviser to Avoro Ventures Fund. Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures. By virtue of these relationships, each of the Reporting Persons may be deemed to beneficially own the securities held by the Funds. F5 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The shares reported herein are held on behalf of the Funds and other managed accounts, within the meaning of Rule 16a-1(a)(2). Read SEC document |
| July 24, 2026 Filed Jul 29, 2026 01:30 UTC | Scribe Therapeutics, Inc. SCTX · Entity 5494 | PurchaseCommon Stock, par value $0.0001 per share | 2,333,333 | $15.00 | $34,999,995.00 |
DisclosureSEC source: 0000902664-26-003270 · ownership.xml · nonDerivative · entry 1 Aghazadeh Behzad · CIK 0001701815 · Director · 10% owner · See Remarks Avoro Capital Advisors LLC · CIK 0001633313 · Director · 10% owner · See Remarks Avoro Ventures LLC · CIK 0001879253 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 3,030,983 F1 · price: The shares reported on this line were purchased from underwriters in the Issuer's initial public offering (the "IPO") at the initial public offering price of $15.00 per share. Of such shares, 2,066,666 shares were purchased on behalf of Avoro Life Sciences Fund LLC ("Avoro Life Sciences") and 266,667 shares were purchased on behalf of Avoro Ventures Fund L.P. ("Avoro Ventures Fund" and, together with Avoro Life Sciences, the "Funds"). F6 · balance_after: The amount reported in Column 5 includes 697,650 shares of Common Stock issuable upon conversion of shares of the Issuer's Series B Preferred Stock held by the Funds, which shares were reported on an as-converted basis in the Reporting Persons' Form 3 filed on July 23, 2026. Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-0.1689 basis at the option of the holder and converted automatically into Common Stock, without the payment of any consideration, upon the closing of the IPO on July 27, 2026. No transaction is reported in Table I or Table II with respect to the conversion. F4 · ownership.nature: The securities reported herein are held directly by Avoro Life Sciences and Avoro Ventures Fund. Avoro Capital Advisors LLC ("Avoro Capital Advisors") serves as investment adviser to Avoro Life Sciences, and Avoro Ventures LLC ("Avoro Ventures") serves as investment adviser to Avoro Ventures Fund. Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures. By virtue of these relationships, each of the Reporting Persons may be deemed to beneficially own the securities held by the Funds. F5 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The shares reported herein are held on behalf of the Funds and other managed accounts, within the meaning of Rule 16a-1(a)(2). Read SEC document |
| July 23, 2026 Filed Jul 28, 2026 01:04 UTC | Scribe Therapeutics, Inc. SCTX · Entity 5494 | GrantStock Option (Right to Buy) · Derivative | 14,725 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0000902664-26-003254 · ownership.xml · derivative · entry 1 Aghazadeh Behzad · CIK 0001701815 · Director · See Remarks Avoro Capital Advisors LLC · CIK 0001633313 · Director · See Remarks Avoro Ventures LLC · CIK 0001879253 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,725 Underlying: Common Stock · 14,725 shares Expires 2036-07-22 F1 · derivative.exercise_date: The options will vest as to 1/3 of the total shares on each of July 23, 2027, July 23, 2028 and July 23, 2029, subject to Behzad Aghazadeh's ("Dr. Aghazadeh") provision of service to the Issuer on each vesting date. F2 · ownership.direct: This Form 4 is filed by Dr. Aghazadeh, Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro Capital Advisors"), and Avoro Ventures LLC, a Delaware limited liability company ("Avoro Ventures," together with Dr. Aghazadeh and Avoro Capital Advisors, the "Reporting Persons"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures LLC. F3 · ownership.direct: The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| June 12, 2026 Filed Jun 15, 2026 21:18 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | GrantStock Option (right to buy) · Derivative | 38,040 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001701815-26-000006 · form4-06152026_090652.xml · derivative · entry 1 Aghazadeh Behzad · CIK 0001701815 · Director · 10% owner · See remarks Avoro Capital Advisors LLC · CIK 0001633313 · Director · 10% owner · See remarks Avoro Ventures LLC · CIK 0001879253 · Director · 10% owner · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,040 Underlying: Common Stock · 38,040 shares Expires 2036-06-12 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026. F2 · balance_after: This Form 4 is filed by Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro Capital Advisors"), Avoro Ventures LLC, a Delaware limited liability company ("Avoro Ventures") and Behzad Aghazadeh ("Dr. Aghazadeh", and together with Avoro Capital Advisors and Avoro Ventures, the "Reporting Persons"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures LLC. F3 · balance_after: The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| May 12, 2026 Filed May 14, 2026 23:40 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | GrantPre-funded Warrant (right to buy) · Derivative | 6,377,714 | $3.92 Strike: $0.00 | $25,000,001.11 |
DisclosureSEC source: 0000902664-26-002449 · ownership.xml · derivative · entry 1 Avoro Capital Advisors LLC · CIK 0001633313 · Director · 10% owner · See Remarks Aghazadeh Behzad · CIK 0001701815 · Director · 10% owner · See Remarks Avoro Ventures LLC · CIK 0001879253 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 14,710,714 Underlying: Common Stock · 6,377,714 shares Expires not disclosed F1 · kind: The securities reported herein were acquired on behalf of accounts managed by Avoro Capital Advisors (as defined below) directly from the Issuer in a private placement. F1 · shares: The securities reported herein were acquired on behalf of accounts managed by Avoro Capital Advisors (as defined below) directly from the Issuer in a private placement. F2 · derivative.exercise_date: Subject to the terms and conditions set forth in the Pre-funded Warrant, the holder thereof may, at any time and from time to time on or after May 12, 2026, exercise the Pre-funded Warrant until it has been exercised in full. Pursuant to the terms of the Pre-Funded Warrant, the Reporting Persons cannot exercise any of the Pre-Funded Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 19.99% of the outstanding Common Stock (the "19.99% Blocker"). Consequently, at this time, the Reporting Persons are not able to exercise all the Pre-Funded Warrants due to the 19.99% Blocker. F2 · derivative.expiration_date: Subject to the terms and conditions set forth in the Pre-funded Warrant, the holder thereof may, at any time and from time to time on or after May 12, 2026, exercise the Pre-funded Warrant until it has been exercised in full. Pursuant to the terms of the Pre-Funded Warrant, the Reporting Persons cannot exercise any of the Pre-Funded Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 19.99% of the outstanding Common Stock (the "19.99% Blocker"). Consequently, at this time, the Reporting Persons are not able to exercise all the Pre-Funded Warrants due to the 19.99% Blocker. F3 · ownership.nature: This Form 4 is filed by Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro Capital Advisors"), Avoro Ventures LLC, a Delaware limited liability company ("Avoro Ventures") and Behzad Aghazadeh ("Dr. Aghazadeh", and together with Avoro Capital Advisors and Avoro Ventures, the "Reporting Persons"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures. F4 · ownership.nature: The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:51 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | GrantStock Option (right to buy) · Derivative | 40,006 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0001415889-25-017406 · form4-06162025_080637.xml · derivative · entry 1 Aghazadeh Behzad · CIK 0001701815 · Director · 10% owner · See remarks Avoro Capital Advisors LLC · CIK 0001633313 · Director · 10% owner · See remarks Avoro Ventures LLC · CIK 0001879253 · Director · 10% owner · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,006 Underlying: Common Stock · 40,006 shares Expires 2035-06-12 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2025. F2 · balance_after: This Form 4 is filed by Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro Capital Advisors"), Avoro Ventures LLC, a Delaware limited liability company ("Avoro Ventures") and Behzad Aghazadeh ("Dr. Aghazadeh", and together with Avoro Capital Advisors and Avoro Ventures, the "Reporting Persons"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures LLC. F3 · balance_after: The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 22:56 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | GrantPre-funded Warrant (right to buy) · Derivative | 8,333,000 | $2.40 Strike: $0.00 | $19,998,366.70 |
DisclosureSEC source: 0000902664-25-001334 · ownership.xml · derivative · entry 1 Aghazadeh Behzad · CIK 0001701815 · Director · 10% owner · See Remarks Avoro Capital Advisors LLC · CIK 0001633313 · Director · 10% owner · See Remarks Avoro Ventures LLC · CIK 0001879253 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 8,333,000 Underlying: Common Stock · 8,333,000 shares Expires not disclosed F1 · kind: The securities reported herein were acquired on behalf of accounts managed by Avoro Capital Advisors and Avoro Ventures (as defined below) directly from the Issuer in a private placement. F2 · derivative.exercise_date: Subject to the terms and conditions set forth in the Pre-funded Warrant, the holder thereof may, at any time and from time to time on or after March 4, 2025, exercise the Pre-funded Warrant until it has been exercised in full. Pursuant to the terms of the Pre-Funded Warrant, the Reporting Persons cannot exercise any of the Pre-Funded Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 19.99% of the outstanding Common Stock (the "19.99% Blocker"). Consequently, at this time, the Reporting Persons are not able to exercise all the Pre-Funded Warrants due to the 19.99% Blocker. F2 · derivative.expiration_date: Subject to the terms and conditions set forth in the Pre-funded Warrant, the holder thereof may, at any time and from time to time on or after March 4, 2025, exercise the Pre-funded Warrant until it has been exercised in full. Pursuant to the terms of the Pre-Funded Warrant, the Reporting Persons cannot exercise any of the Pre-Funded Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 19.99% of the outstanding Common Stock (the "19.99% Blocker"). Consequently, at this time, the Reporting Persons are not able to exercise all the Pre-Funded Warrants due to the 19.99% Blocker. F3 · ownership.nature: This Form 4 is filed by Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro Capital Advisors"), Avoro Ventures LLC, a Delaware limited liability company ("Avoro Ventures") and Behzad Aghazadeh ("Dr. Aghazadeh", and together with Avoro Capital Advisors and Avoro Ventures, the "Reporting Persons"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures. F4 · ownership.nature: The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:12 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | GrantStock Option (right to buy) · Derivative | 45,832 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001415889-24-016874 · form4-06142024_080636.xml · derivative · entry 1 Aghazadeh Behzad · CIK 0001701815 · Director · 10% owner · See remarks Avoro Capital Advisors LLC · CIK 0001633313 · Director · 10% owner · See remarks Avoro Ventures LLC · CIK 0001879253 · Director · 10% owner · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,832 Underlying: Common Stock · 45,832 shares Expires 2034-06-12 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2024. F2 · balance_after: This Form 4 is filed by Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro Capital Advisors"), Avoro Ventures LLC, a Delaware limited liability company ("Avoro Ventures") and Behzad Aghazadeh ("Dr. Aghazadeh", and together with Avoro Capital Advisors and Avoro Ventures, the "Reporting Persons"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures LLC. F3 · balance_after: The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| June 15, 2023 Filed Jun 21, 2023 00:59 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | GrantStock Option (right to buy) · Derivative | 28,255 | $0.00 Strike: $8.20 | $0.00 |
DisclosureSEC source: 0001209191-23-038675 · doc4.xml · derivative · entry 1 Aghazadeh Behzad · CIK 0001701815 · Director · 10% owner · See remarks Avoro Capital Advisors LLC · CIK 0001633313 · Director · 10% owner · See remarks Avoro Ventures LLC · CIK 0001879253 · Director · 10% owner · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,255 Underlying: Common Stock · 28,255 shares Expires 2033-06-15 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 15, 2023. F2 · ownership.direct: This Form 4 is filed by Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro Capital Advisors"), Avoro Ventures LLC, a Delaware limited liability company ("Avoro Ventures") and Behzad Aghazadeh ("Dr. Aghazadeh", and together with Avoro Capital Advisors and Avoro Ventures, the "Reporting Persons"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures LLC. F3 · ownership.direct: The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| September 22, 2022 Filed Sep 26, 2022 21:46 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | GrantCommon Stock, $0.0001 par value per share ("Common Stock") | 1,260,000 | $12.50 | $15,750,000.00 |
DisclosureSEC source: 0000902664-22-004356 · ownership.xml · nonDerivative · entry 1 Aghazadeh Behzad · CIK 0001701815 · Director · 10% owner · See Remarks Avoro Capital Advisors LLC · CIK 0001633313 · Director · 10% owner · See Remarks Avoro Ventures LLC · CIK 0001879253 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 3,471,752 F1 · kind: The securities reported herein were acquired on behalf of accounts managed by Avoro Capital Advisors and Avoro Ventures (as defined below) directly from the Issuer in a private placement. F2 · ownership.nature: This Form 4 is filed by Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro Capital Advisors"), Avoro Ventures LLC, a Delaware limited liability company ("Avoro Ventures") and Behzad Aghazadeh ("Dr. Aghazadeh", and together with Avoro Capital Advisors and Avoro Ventures, the "Reporting Persons"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures. F3 · ownership.nature: The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:21 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | GrantStock Option (right to buy) · Derivative | 18,573 | $0.00 Strike: $13.46 | $0.00 |
DisclosureSEC source: 0001209191-22-037859 · doc4.xml · derivative · entry 1 Aghazadeh Behzad · CIK 0001701815 · Director · 10% owner · See remarks Avoro Capital Advisors LLC · CIK 0001633313 · Director · 10% owner · See remarks Avoro Ventures LLC · CIK 0001879253 · Director · 10% owner · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,573 Underlying: Common Stock · 18,573 shares Expires 2032-06-15 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of the (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 15, 2022. F2 · ownership.direct: This Form 4 is filed by Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro Capital Advisors"), Avoro Ventures LLC, a Delaware limited liability company ("Avoro Ventures") and Behzad Aghazadeh ("Dr. Aghazadeh", and together with Avoro Capital Advisors and Avoro Ventures, the "Reporting Persons"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures LLC. F3 · ownership.direct: The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 27, 2021 Filed Aug 30, 2021 23:39 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | GrantStock option (right to buy) · Derivative | 17,549 | $0.00 Strike: $26.00 | $0.00 |
DisclosureSEC source: 0000902664-21-004071 · ownership.xml · derivative · entry 2 Aghazadeh Behzad · CIK 0001701815 · Director · 10% owner · See Remarks Avoro Capital Advisors LLC · CIK 0001633313 · Director · See Remarks Avoro Ventures LLC · CIK 0001879253 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,549 Underlying: Common Stock · 17,549 shares Expires 2031-08-27 F4 · derivative.exercise_date: In connection with the closing of the Merger, as approved by the stockholders of the Issuer on August 17, 2021, the Board granted on August 26, 2021 to the Reporting Person an Initial Award (as defined in the Issuer's Outside Director Compensation Policy and in accordance with the Issuer's 2021 Equity Incentive Plan (the "Plan")). Subject to the Reporting Person continuing to be a Service Provider (as defined in the Plan) through each applicable date, the Initial Award is scheduled to vest as to one thirty-sixth (1/36th) of the shares of common stock subject to the Initial Award on a monthly basis following the grant date on the same day of the month as the grant date (and if there is no corresponding day, on the last day of the month). The grant date is August 27, 2021. F1 · ownership.direct: This Form 4 is filed by Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro Capital Advisors"), Avoro Ventures LLC, a Delaware limited liability company ("Avoro Ventures") and Behzad Aghazadeh ("Dr. Aghazadeh", and together with Avoro Capital Advisors and Avoro Ventures, the "Reporting Persons"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures LLC. F2 · ownership.direct: The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. F4 · ownership.direct: In connection with the closing of the Merger, as approved by the stockholders of the Issuer on August 17, 2021, the Board granted on August 26, 2021 to the Reporting Person an Initial Award (as defined in the Issuer's Outside Director Compensation Policy and in accordance with the Issuer's 2021 Equity Incentive Plan (the "Plan")). Subject to the Reporting Person continuing to be a Service Provider (as defined in the Plan) through each applicable date, the Initial Award is scheduled to vest as to one thirty-sixth (1/36th) of the shares of common stock subject to the Initial Award on a monthly basis following the grant date on the same day of the month as the grant date (and if there is no corresponding day, on the last day of the month). The grant date is August 27, 2021. Read SEC document |
| August 26, 2021 Filed Aug 30, 2021 23:39 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | GrantCommon Stock, $0.0001 par value per share ("Common Stock") | 1,911,752 | $13.08 | $24,999,980.90 |
DisclosureSEC source: 0000902664-21-004071 · ownership.xml · nonDerivative · entry 1 Aghazadeh Behzad · CIK 0001701815 · Director · 10% owner · See Remarks Avoro Capital Advisors LLC · CIK 0001633313 · Director · See Remarks Avoro Ventures LLC · CIK 0001879253 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 2,211,752 F1 · ownership.nature: This Form 4 is filed by Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro Capital Advisors"), Avoro Ventures LLC, a Delaware limited liability company ("Avoro Ventures") and Behzad Aghazadeh ("Dr. Aghazadeh", and together with Avoro Capital Advisors and Avoro Ventures, the "Reporting Persons"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures LLC. F2 · ownership.nature: The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. F3 · ownership.nature: The securities reported herein were acquired on behalf of accounts managed by Avoro Capital Advisors and Avoro Ventures directly from the Issuer in a PIPE financing completed in connection with the closing of the Agreement and Plan of Merger between the Issuer and Aadi Bioscience, Inc., dated as of May 16, 2021, following which the Issuer changed its name to Aadi Bioscience, Inc. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.